CA3061088A1 - Parathyroid hormone fusion polypeptide - Google Patents

Parathyroid hormone fusion polypeptide Download PDF

Info

Publication number
CA3061088A1
CA3061088A1 CA3061088A CA3061088A CA3061088A1 CA 3061088 A1 CA3061088 A1 CA 3061088A1 CA 3061088 A CA3061088 A CA 3061088A CA 3061088 A CA3061088 A CA 3061088A CA 3061088 A1 CA3061088 A1 CA 3061088A1
Authority
CA
Canada
Prior art keywords
fusion polypeptide
amino acid
seq
acid sequence
parathyroid hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3061088A
Other languages
English (en)
French (fr)
Inventor
Ian Wilkinson
Richard Ross
Original Assignee
Unversity Of Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unversity Of Sheffield filed Critical Unversity Of Sheffield
Publication of CA3061088A1 publication Critical patent/CA3061088A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3061088A 2017-04-28 2018-04-27 Parathyroid hormone fusion polypeptide Pending CA3061088A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1706781.0A GB201706781D0 (en) 2017-04-28 2017-04-28 Parathyroid hormone fusion polypeptide
GB1706781.0 2017-04-28
PCT/GB2018/051120 WO2018197895A2 (en) 2017-04-28 2018-04-27 Parathyroid hormone fusion polypeptide

Publications (1)

Publication Number Publication Date
CA3061088A1 true CA3061088A1 (en) 2018-11-01

Family

ID=59011076

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3061088A Pending CA3061088A1 (en) 2017-04-28 2018-04-27 Parathyroid hormone fusion polypeptide

Country Status (7)

Country Link
US (2) US11344606B2 (https=)
EP (1) EP3609913A2 (https=)
JP (2) JP2020519250A (https=)
CN (1) CN110546159B (https=)
CA (1) CA3061088A1 (https=)
GB (1) GB201706781D0 (https=)
WO (1) WO2018197895A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201706781D0 (en) * 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
IL284533B2 (en) * 2019-01-11 2024-02-01 Radius Health Inc Methods for detecting antibodies to neutralizing thyroid hormone (PTH) and thyroid hormone-related peptide (PTHRP) analog
CN111876388A (zh) * 2020-07-24 2020-11-03 赛瑞诚(苏州)生物科技有限公司 一种骨和骨组织靶向外泌体及其制备方法和应用
CN118126197B (zh) * 2024-03-19 2025-02-25 康众(广东)生物医药有限公司 一种重组pth融合蛋白及其构建方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
JPH11285388A (ja) 1998-04-03 1999-10-19 Jcr Pharmaceuticals Co Ltd キメラレセプター発現細胞とその用途
EP2348047A1 (en) 2000-04-21 2011-07-27 New England Medical Center G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
EP1771467A2 (en) 2004-07-26 2007-04-11 Asterion Limited Linkers
KR100700869B1 (ko) 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
CA2930681C (en) 2007-04-09 2019-10-15 The Board Of Trustees Of The University Of Arkansas Fusion protein of collagen-binding domain and parathyroid hormone
GB0717985D0 (en) 2007-07-20 2007-10-24 Asterion Ltd Growth hormone fusion proteins
WO2010111617A2 (en) 2009-03-27 2010-09-30 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
JP2013519699A (ja) 2010-02-16 2013-05-30 ノヴォ ノルディスク アー／エス 因子ｖｉｉｉ融合タンパク質
MX358161B (es) 2010-05-13 2018-08-06 The General Hospital Corp Star Analogos de hormona paratiroidea y usos para los mismos.
GB201104285D0 (en) * 2011-03-15 2011-04-27 Asterion Ltd Modified receptor fusion proteins
US9579273B2 (en) 2011-12-14 2017-02-28 The Kitasato Institute Delivery of therapeutic agents by a collagen binding protein
WO2013120060A1 (en) 2012-02-09 2013-08-15 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents by a collagen binding protein
JP2015504087A (ja) 2012-01-20 2015-02-05 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ 安定化ｐｔｈ製剤
AU2014296288B2 (en) * 2013-07-31 2020-02-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using PTH-related and EGF-related molecules
JP6805174B2 (ja) 2015-05-12 2020-12-23 アメリカ合衆国 神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むａａｖ分離株及び融合タンパク質
GB201706781D0 (en) * 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide

Also Published As

Publication number Publication date
US11344606B2 (en) 2022-05-31
US20200164033A1 (en) 2020-05-28
JP2020519250A (ja) 2020-07-02
EP3609913A2 (en) 2020-02-19
JP2023027315A (ja) 2023-03-01
GB201706781D0 (en) 2017-06-14
CN110546159A (zh) 2019-12-06
CN110546159B (zh) 2023-08-22
WO2018197895A3 (en) 2019-01-17
US20220218790A1 (en) 2022-07-14
WO2018197895A2 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
US20220218790A1 (en) Parathyroid hormone fusion polypeptide
AU2002213843B2 (en) Apolipoprotein analogues
CN104736557B (zh) 嵌合成纤维细胞生长因子21蛋白及其使用方法
US8809499B2 (en) Fusion protein of human fibroblast growth factor-21 and exendin-4
US10822386B2 (en) Insulin analogues with enhanced stability and reduced mitogenicity
US7223726B2 (en) Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
KR20180052545A (ko) 융합 단백질을 포함하는 간염증, 간섬유화 및 간경화 예방 또는 치료용 약학적 조성물
KR20100043201A (ko) 성장 호르몬 융합 단백질
WO2015031316A1 (en) Methods of using interleukin-10 for treating diseases and disorders
CN104968674A (zh) 具有胆固醇流出活性的新颖的glp-1受体激动剂
JP2018505874A (ja) 選択的シグナリング特性及びより低い分裂促進性を有するインスリンアナログ
CN113105561A (zh) 一种双靶点融合蛋白的制备方法和应用
JP2018502908A (ja) アルファ‐１‐ アンチトリプシン（ａ１ａｔ）融合タンパク質及びその使用
EP2948166B1 (en) N-terminal truncated insulin analogues
EP0832221A1 (en) Bone stimulating factor
US20220135640A1 (en) Cortistatin or an analogue thereof as a pharmaceutically active agent in latent form
AU2008201887B2 (en) Apolipoprotein analogues
WO2015193378A1 (en) Novel glp-1 receptor agonists with cholesterol efflux activity
Rand-Weaver et al. A rapid procedure for the isolation of bioactive growth hormone
RU2792236C1 (ru) Производное полипептида и способ его получения
EP2768520A1 (en) Chemically and thermodynamically stable insulin analogues and improved methods for their production
KR20180132833A (ko) Mcm 결핍과 관련된 장애의 치료를 위한 메틸말로닐 조효소 a 뮤타아제 (mcm) 융합 구조체
Delgado Mora et al. Cortistatinor an analogue thereof as a pharmaceutically active agent in latent form
WO2025226713A1 (en) Compositions and methods for producing active proteins from inactive proproteins
US20030027753A1 (en) Bone stimulating factor

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220505

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20241029

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20251029

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251230